Objective response rate

Nearly all patients achieved a response (n=52/60) and 62% of patients achieved CR with TECARTUS at a median study follow-up of 12.3 months1,2

PR 25% (95% CI:15, 38 n=15/60), 87% ORR (95% CI: 75, 94 n=52/60), and CR 62% (95% CI: 48, 74 n=37/60) PR 25% (95% CI:15, 38 n=15/60), 87% ORR (95% CI: 75, 94 n=52/60), and CR 62% (95% CI: 48, 74 n=37/60)

Pinch to zoom

Responses were rapid—the median time to initial response was 1 month (range: 0.8-3.1 months)1,3

  • Median time to complete response was 3 months (range: 1.0-9.3 months)

Many responses deepened over time3

  • 76% (n=28/37) of patients who achieved CR converted from PR or stable disease
    • Of the 76% of patients who converted to CR, most (n=25/28) converted from PR
    • Conversions occurred as late as 8.3 months postinfusion

Consistent response rates demonstrated across efficacy analyses1

Response Rates in ZUMA-2 Response Rates in ZUMA-2

*Among all responders. DOR is measured from the date of first objective response to the date of progression or death.1

Duration of response

With TECARTUS, median duration of response was not reached at a median study follow-up of 12.3 months1-3*

  • DOR was a secondary endpoint of the ZUMA-2 phase 2, single-arm, open-label study
  • DOR data below are descriptive and should be carefully interpreted in light of the single-arm design
Duration of Response over time (months) - chart Duration of Response over time (months) - chart

Pinch to zoom

  • 62% (n=32/52) of all patients who responded and 81% (n=30/37) of patients with a CR remained in remission at the time of analysis1,3
    • Median duration of follow-up for DOR in all responders was 8.6 months (range: 7.9-20.9 months) and in patients with a CR was 8.5 months (range: 7.8-20.9 months)3

Long-term follow-up

  • In the patients with ≥2 years follow-up, 43% (n=12/28) had an ongoing response3

Duration of response was consistent across efficacy analyses1

Duration of Response in ZUMA-2 Duration of Response in ZUMA-2

Brexucabtagene autoleucel (TECARTUS) is recommended by the NCCN Guidelines® for B-Cell Lymphomas for the treatment of adults with R/R MCL following chemoimmunotherapy and a BTKi (category 2A)4

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

*Kaplan-Meier estimate based on the 52 patients with a response.3

A + sign indicates a censored value.

CI=confidence interval; CR=complete response; DOR=duration of response; ITT=intent-to-treat; MCL=mantle cell lymphoma; NE=not estimable; NR=not reached; OR=objective response; ORR=objective response rate; PR=partial response; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Data on file [1]. Kite Pharma, Inc; 2020. 3. Data on file [2]. Kite Pharma, Inc; 2020. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas. V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed February 23, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.